However, its marked downregulation in ccRCC and ppRCC may contribute to the poor prognosis of these RCC subtypes and investigation of the effects of in vivo modulation of CD9 signaling in RCC could be productive. The gene discussed is CD9; the disease is nonpapillary renal cell carcinoma.